The Of Does Tribulus Terrestris Really Work? An Evidence-Based Look

The primary objectives were to compare the efficacy of extracts of the plant Tribulus terrestris (TT; marketed as Tribestan), in comparison with placebo, for the treatment of males with impotence (ED) and with or without hypoactive sexual desire disorder (HSDD), as well as to monitor the security profile of the drug.

Stage IV, prospective, randomized, double-blind, placebo-controlled medical trial in parallel groups. This research study consisted of 180 males aged in between 18 and 65 years with moderate or moderate ED and with or without HSDD: 90 were randomized to TT and 90 to placebo. Patients with ED and high blood pressure, diabetes mellitus, and metabolic syndrome were consisted of in the study.

Each Tribestan film-coated tablet contains the active substance Tribulus terrestris, herba extractum siccum (35-45:1) 250mg which is standardized to furostanol saponins (not less than 112. 5mg). Each patient got orally 32 film-coated tablets daily after meals, during the 12-week treatment period. At the end of every month, individuals' sexual function, including ED, was assessed by International Index of Erectile Function (IIEF) Questionnaire and Global Effectiveness Concern (GEQ).

The primary outcome measure was the modification in IIEF rating after 12 weeks of treatment. Complete randomization (random sorting using maximum allowable% variance) with an equal number of clients in each sequence was utilized. This randomization algorithm has the restriction that unequal treatment allocation is not enabled; that is, all groups must have the same target sample size.

All outcome assessors were also blinded to group allocation. 86 patients in each group completed the research study. The IIEF score enhanced substantially in the TT group compared with the placebo group (